Insilico Sets Benchmark for AI Drug Discovery

The key difference is that Insilico has already turned AI drug discovery into a repeatable operating system, not just a research promise. It has moved from target finding to candidate nomination, IND filings, partnered programs, and a Phase III asset, while also selling software and licensing molecules. Isomorphic has bigger capital backing and elite structure biology roots, but its public proof is still concentrated in partnerships rather than disclosed clinical assets or trial timelines.

• Insilico’s benchmark is concrete. Its platform has produced more than 40 programs, 31 to 32 nominated preclinical candidates, 13 IND approved or cleared programs, and rentosertib in Phase III for idiopathic pulmonary fibrosis in China. That means the models have already fed real regulatory and trial workflows.
  1 sacra 2 insilico 3 insilico
• Its business model is also more flexible. Insilico both licenses discovery software and out licenses drug assets, which lets it get paid earlier through platform deals, then again if molecules advance. The company says it works with 13 of the top 20 global pharma companies, showing broad buyer acceptance.
  1 sacra 2 insilico 4 isomorphiclabs
• Isomorphic’s public traction is strongest in high value pharma collaborations. Lilly and Novartis signed deals in January 2024, and Novartis expanded in February 2025. That validates buyer interest in its platform, but it is still a step earlier than naming a candidate, filing an IND, or starting a trial.
  5 isomorphiclabs 6 googleapis 7 sacra

The next competitive test is whether Isomorphic can convert world class modeling into disclosed development milestones. In this market, the winners will be the companies that show molecules entering the clinic, not just models attracting partners. Insilico has set the current benchmark for that transition, and others now have to match it program by program.